← 홈

흑색종

106개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 106개
AntibodystaleBristol Myers SquibbPhase 2

Ipilimumab Injection [Yervoy] (Ipilimumab Injection [Yervoy])

Malignant Melanoma · Malignant Melanoma

#MalignantMelanoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

Ipilimumab and Fotemustine (Ipilimumab and Fotemustine)

Metastatic Malignant Melanoma · Metastatic Malignant Melanoma

#MetastaticMalignantMelanoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Ipilimumab plus nivolumab plus guadecitabine)

Melanoma; Non Small Cell Lung Cancer · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

pembrolizumab (Keytruda, Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab)

Metastatic Cancer; Melanoma Cancer · Metastatic Cancer

#MetastaticCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

Ocular (Ipilimumab: Cohort 2, Ipilimumab: Cohort 2 (Ocular))

Metastatic Melanoma · Metastatic Melanoma

#MetastaticMelanoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 1%임상시험 1상태 ACTIVE
AntibodystaleBrown UniversityPhase 2

Ipilumumab (Ipilumumab)

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleOslo University HospitalPhase 2

pembrolizumab (Keytruda, LTX-315 + pembrolizumab)

Melanoma Stage IIIB-IV · Melanoma Stage IIIB-IV

#MelanomaStageIIIB-IV#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleIovance Biotherapeutics, Inc.Phase 3

pembrolizumab (Keytruda, Lifileucel plus Pembrolizumab)

Metastatic Melanoma; Unresectable Melanoma · Metastatic Melanoma

#MetastaticMelanoma#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleNYU Langone HealthPhase 1

nivolumab (Opdivo, Mocetinostat Induction Phase + Ipilimumab + Nivolumab)

Melanoma · Melanoma

#Melanoma#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleNYU Langone HealthPhase 1

nivolumab (Opdivo, Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab)

Melanoma · Melanoma

#Melanoma#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 DISCONTINUED
CGTBiologicstaleShenzhen Geno-Immune Medical In…Phase 2

NG2 and DLL3 CAR-T cells (NG2 and DLL3 CAR-T cells)

Melanoma · Melanoma

#Melanoma#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
CGTBiologicstaleCentre Hospitalier Universitair…Phase 1

NY-ESO-1 TCR redirected autologous T cell product (NY-ESO-1 TCR redirected autologous T cell product)

Advanced Melanoma; Melanoma Metastatic · Advanced Melanoma

#AdvancedMelanoma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleUniversity of PennsylvaniaPhase 1

NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1 (NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1)

Multiple Myeloma; Melanoma · PD-1

#PD-1#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 DISCONTINUED
AntibodystaleBristol Myers SquibbPhase 3

nivolumab (Opdivo, Neoadjuvant ipilimumab + nivolumab)

Malignant Melanoma Stage III · Malignant Melanoma Stage III

#MalignantMelanomaStageIII#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab and Relatlimab)

Metastatic Melanoma; Liver Metastases · Metastatic Melanoma

#MetastaticMelanoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab and/or Ipilimumab)

Mucosal Melanoma · Mucosal Melanoma

#MucosalMelanoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

Cutaneous (Nivolumab: Cohort 1, Nivolumab: Cohort 1 (Cutaneous))

Metastatic Melanoma · Metastatic Melanoma

#MetastaticMelanoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 1%임상시험 1상태 ACTIVE
AntibodystaleBristol Myers SquibbPhase 2

Ocular (Nivolumab: Cohort 2, Nivolumab: Cohort 2 (Ocular))

Metastatic Melanoma · Metastatic Melanoma

#MetastaticMelanoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 1%임상시험 1상태 ACTIVE
AntibodystaleMerckPhase 2

anti-PD-1 (Pembrolizumab, Pembrolizumab (anti-PD-1))

Unresectable Melanoma; Metastatic Melanoma · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 DISCONTINUED
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab - additional treatment)

Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting · Metastatic Melanoma Naive to Immune Ther

#MetastaticMelanomaNaivetoImmuneT#Antibody#Phase2#항체#면역항체+2
효능 ORR 79%임상시험 1상태 RECRUITING

4 / 6 페이지

← 이전다음 →